1625 Results (Page 65 of 65)
Rare Diseases Markets Research Reports
Australia Hemophilia B Drugs Market Analysis
Australia Hemophilia B Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hemophilia B is growing rapidly as a result of increasing patient awareness and diagnosis, advancements in treatment options, increasing research and development investments, stratergic collaborations and partnerships between research organizations and pharmaceutical companies. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. Takeda Pharmaceutical Company Limited (previously Shire), Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.
Egypt Acromegaly Therapeutics Market Analysis
Egypt Acromegaly Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The prevalence and incidence of acromegaly and pituitary tumours are rising, as is global awareness of the disease. Technological advances in the development of new acromegaly medications are also key contributors to the market's growth. The high prevalence of hormonal problems, evolving lifestyles, and rising genetic disease incidence are all anticipated to fuel market expansion.Some of the key players in the global acromegaly therapeutics Market include Roche, Sanofi, GSK, Pfizer INC., Ipsen, Chiasma Inc, Validus pharmaceuticals LLC., Novartis AG, Amryt, Recordati, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals , and Others.
Canada Myasthenia Gravis Drugs Market Analysis
Canada Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
France Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
France Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Spain Hyperhidrosis Therapeutics Market Analysis
Spain hyperhidrosis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The increase in disease incidence, particularly axillary hyperhidrosis in industrialised nations, is one of the causes driving the market for hyperhidrosis treatments. Additionally, it is projected that increasing healthcare service demand will considerably fuel market growth, along with an increase in new product releases and product approvals.The global hyperhidrosis treatment market?s major key players are AbbVie Inc. (Allergan PLC), Brickell Biotech Inc., Eli Lilly and Company (Dermira), 1315 Capital (miraDry Inc.), SweatBlock, Merz Pharma (Merz Aesthetics), Dermavant Sciences Inc. (Roivant Sciences), Advin Health Care, Dermadry Laboratories Inc., and Dermata Therapeutics Inc
India Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis
India Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
Australia Hemophilia Market Analysis
Australia Hemophilia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The ability of a person's blood to clot is impaired by haemophilia A and haemophilia B, two rare congenital lifelong bleeding disorders that can cause excessive bleeding and spontaneous bleeding into joints, which can cause joint damage and chronic pain and have a significant impact on quality of life. The rise in haemophilia prevalence, improvements in treatment technology, and supportive governmental activities for haemophilia management are all contributing factors to the market share growth for haemophilia treatments. In the "Global Hemophilia market," the following firms are described: Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., Baxter International, Inc., and Hospira Inc.
Egypt Adrenoleukodystrophy (ALD) Therapeutics Market Analysis
Egypt Adrenoleukodystrophy (ALD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Drivers of acromegaly market are increasing cases of the disorder which in turn increased awareness and government focus motivated financial support to R&D. Poxel SA, Bluebird Bio Inc.,Viking Technologies, Minoryx Therapeutics sl., Apteeus SAS, Ashvattha Therapeutics LLC, NeuroVia Company, Autobahn Therapeutics Inc., Aldagen Inc., Celularity Inc., Imstem Biotechnology Inc., MedDay SA, and Orpheris Inc. are major competitors in the Egypt Adrenoleukodystrophy (ALD) drugs market.
Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis
Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
India Scleroderma Therapeutics Market Analysis
India Scleroderma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rapid rise in scleroderma prevalence, rising frequencies of genetic anomalies, and considerable environmental changes occurring all over the world are all predicted to accelerate market expansion.Major global players in Scleroderma Therapeutics Market are Emerald Health Pharmaceuticals, Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Corbus Pharmaceuticals Holdings, Inc., Boehringer Ingelheim International GmbH, Sanofi, Allergan, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Kadmon Holdings, Inc., Johnson & Johnson Private Limited, Liminal BioSciences Inc and AstraZeneca.
Australia Hemostasis Products Market Analysis
Australia Hemostasis Products market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for hemostasis products is growing rapidly as a result of rising prevalence of cardiovascular diseases worldwide due to adoption of unhealthy lifestyle, consumption of unhealthy food products and rising illnesses among the population, rising medical tourism, higher investments by government in research and development of hemostasis products, huge base of geriatric population coupled with large number of blood disorders patient population, increasing demand for minimally invasive surgeries, adoption of advanced hemostasis products by patients . Abbott Laboratories, Baxter International, CSL Behring, Hem Con Medical Technologies, Grifols, Johnson & Johnson, Medtronic, Pfizer, integra Life Sciences Corporation, C. R. Bard, Inc. are the key market players operating in global hemostasis products market.
Egypt Alport Syndrome Therapeutics Market Analysis
Egypt during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.
Australia Hereditary Angioedema Drugs Market Analysis
Australia Hereditary Angioedema Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hereditary Angioedema Drugs is growing as a result of Increasing Awareness and Diagnosis of disease, Advancements in Treatment Options, Technological Advancements and the regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.
Egypt Anal Fistula Therapeutics Market Analysis
Egypt During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.
Canada POMC Genetic Obesity Drugs Market Analysis
Canada POMC Genetic Obesity Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for POMC Genetic Obesity Drugs is growing due to increase spending in research and development activities by pharmaceutical companies, introduction of new emerging therapies like gene editing and gene replacement approaches, incentives provided by regulatory body?s in the form of orphan drug designations. Novo Nordisk A/S , rhythm Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated ,Amgen Inc are the key market players operating in global POMC genetic obesity drugs market.
France Colorectal Cancer Therapeutics Market Analysis
France Colorectal Cancer Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Colon cancer, commonly known as colorectal cancer (CRC), is a condition that affects the large intestine. It is a type of cancer that develops in the colon or rectum. The surge in product introductions and colorectal cancer awareness are two factors driving the global market for drugs to treat the disease. The high incidence of colorectal cancer, which contributes to high mortality rates, and the rising global desire for more potent treatments are additional important driving forces. Genentech, Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, Sanofi, Merck Sharp & Dohme Corp., Taiho Pharmaceutical (Otsuka Pharmaceutical Co., Ltd.), Bayer AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Ipsen Biopharmaceuticals, Inc., and numerous other global companies participate in the colorectal cancer therapeutics
Australia Hodgkins Lymphoma Drugs Market Analysis
Australia Hodgkins Lymphoma Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030.The market for Hodgkins Lymphoma Drugs is rising due to Increasing incidence of Hodgkin lymphoma, Extensive research and development activities, Growing adoption of immunotherapies, Increasing awareness and diagnosis about disease, Improved reimbursement policies and increased insurance coverage for cancer treatments along with growing availability of targeted therapies and combination therapies for Hodgkin Lymphoma Drugs. Bristol Myers Squibb, Merck & Co., Inc. (MSD), Takeda Pharmaceutical Company Limited, Roche Holding AG, Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, AbbVie Inc., Celgene Corporation (a subsidiary of Bristol Myers Squibb), Amgen Inc., Gilead Sciences, Inc. are the global companies in Hodgkins Lymphoma Drugs market.
Egypt Angelman Syndrome Therapeutics Market Analysis
Egypt During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.
Canada Pompe Disease Drugs Market Analysis
Canada Pompe Disease Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pompe disease Drugs is growing due to increase in awareness about the disease , better diagnosis, advancements in treatment options and increase in research and development activities by different pharmaceutical companies and research organizations. Sanofi Genzyme ,BioMarin Pharmaceutical Inc., Avrobio Inc., Amicus Therapeutics Inc. are the key market players operating in global pompe disease market.
France Cryptococcosis Therapeutics Market Analysis
France Cryptococcosis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The pathogenic yeasts in the genus Cryptococcus that cause cryptococcosis have a wide range of clinical manifestations and are contagious throughout the world. Currently, Cryptococcus neoformans and Cryptococcus gattii are the two species of the bacteria most frequently linked to human illness. The market for disorders caused by cryptococcosis is expanding as a result of the rising prevalence of the condition and the availability of cutting-edge treatments. Bristol-Myers Squibb, Abbott Laboratories, Pfizer, Glenmark Pharmaceuticals, Bausch Health, Johnson & Johnson, Novartis AG, Janssen Biotech, Sigmapharm Laboratories, Matinas BioPharma, Mycovia Pharmaceuticals, Aparna Biosciences, FUJIFILM Toyama Chemical, TGV Therapeutics, Amplyx Pharmaceuticals, and many others are leading companies in the global market for Cryptococcosis therapeutics.
India Wilson?s Disease Therapeutics Market Analysis
India Wilson?s Disease Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Therapeutics is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques, increase in awareness about the disease due to patient advocacy programmers, support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in Wilson?s Disease Therapeutics market.
Australia Huntington's Disease Drugs Market Analysis
Australia Huntington's Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease especially rise in disease modifying therapies, incentives provided by regulatory authorities like orphan drug designations. Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (spain).
Egypt Ankylosing Spondylitis Therapeutics Market Analysis
Egypt Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
US Myasthenia Gravis Therapeutics Market Analysis
The US Myasthenia Gravis therapeutics market is projected to grow from $418.4 Mn in 2022 to $724.3 Mn by 2030, registering a CAGR of 7.1% during the forecast period of 2022-30. This market engages in all of these activities, including regulatory approvals, the introduction of new products, the purchase of other companies, and joint ventures with them. These strategies will definitely contribute to the growth of the global industry. Major global players in this market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., and Astellas Pharma, Inc.
US Multiple Sclerosis Therapeutics Market Analysis
The US multiple sclerosis therapeutics market is projected to grow from $18.2 Bn in 2022 to $27.7 Bn by 2030, registering a CAGR of 5.38% during the forecast period of 2022?30. The two reasons propelling market expansion are the prevalence of multiple sclerosis (MS) is rising, and funding for MS research is rising as well. Major global players in this market are Abbott (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Takeda Pharmaceutical Company Limited (Japan), Jazz Pharmaceuticals, Inc. (U.K.), Novartis AG (Switzerland), Biora Therapeutics, Inc. (U.S.), Bausch Health Companies Inc. (Canada), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and Mylan N.V. (U.S.)
